Logo image of IRON

DISC MEDICINE INC (IRON) Stock Fundamental Analysis

NASDAQ:IRON - Nasdaq - US2546041011 - Common Stock - Currency: USD

51.61  +1.52 (+3.03%)

After market: 51.61 0 (0%)

Fundamental Rating

2

IRON gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 558 industry peers in the Biotechnology industry. The financial health of IRON is average, but there are quite some concerns on its profitability. IRON does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year IRON has reported negative net income.
IRON had a negative operating cash flow in the past year.
In the past 5 years IRON always reported negative net income.
In the past 5 years IRON always reported negative operating cash flow.
IRON Yearly Net Income VS EBIT VS OCF VS FCFIRON Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

IRON's Return On Assets of -16.42% is amongst the best of the industry. IRON outperforms 80.07% of its industry peers.
The Return On Equity of IRON (-17.64%) is better than 86.36% of its industry peers.
Industry RankSector Rank
ROA -16.42%
ROE -17.64%
ROIC N/A
ROA(3y)-22.05%
ROA(5y)-23.6%
ROE(3y)-24.43%
ROE(5y)-26.32%
ROIC(3y)N/A
ROIC(5y)N/A
IRON Yearly ROA, ROE, ROICIRON Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -10 -20 -30 -40 -50

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for IRON so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IRON Yearly Profit, Operating, Gross MarginsIRON Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

5

2. Health

2.1 Basic Checks

The number of shares outstanding for IRON has been increased compared to 1 year ago.
Compared to 1 year ago, IRON has a worse debt to assets ratio.
IRON Yearly Shares OutstandingIRON Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
IRON Yearly Total Debt VS Total AssetsIRON Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

IRON has an Altman-Z score of 21.79. This indicates that IRON is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of IRON (21.79) is better than 94.25% of its industry peers.
IRON has a Debt/Equity ratio of 0.04. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.04, IRON is doing worse than 61.76% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Altman-Z 21.79
ROIC/WACCN/A
WACCN/A
IRON Yearly LT Debt VS Equity VS FCFIRON Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 100M 200M 300M 400M

2.3 Liquidity

A Current Ratio of 37.65 indicates that IRON has no problem at all paying its short term obligations.
IRON's Current ratio of 37.65 is amongst the best of the industry. IRON outperforms 98.74% of its industry peers.
A Quick Ratio of 37.65 indicates that IRON has no problem at all paying its short term obligations.
The Quick ratio of IRON (37.65) is better than 98.74% of its industry peers.
Industry RankSector Rank
Current Ratio 37.65
Quick Ratio 37.65
IRON Yearly Current Assets VS Current LiabilitesIRON Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for IRON have decreased strongly by -18.43% in the last year.
EPS 1Y (TTM)-18.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%6.42%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 19.23% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-19.64%
EPS Next 2Y-13.62%
EPS Next 3Y-0.99%
EPS Next 5Y19.23%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
IRON Yearly Revenue VS EstimatesIRON Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
IRON Yearly EPS VS EstimatesIRON Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -20 -40

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

IRON reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year IRON is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IRON Price Earnings VS Forward Price EarningsIRON Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IRON Per share dataIRON EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 15

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-13.62%
EPS Next 3Y-0.99%

More info and screens

0

5. Dividend

5.1 Amount

IRON does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

DISC MEDICINE INC

NASDAQ:IRON (6/20/2025, 8:00:02 PM)

After market: 51.61 0 (0%)

51.61

+1.52 (+3.03%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-07 2025-05-07/bmo
Earnings (Next)08-06 2025-08-06/bmo
Inst Owners85.98%
Inst Owner Change23.7%
Ins Owners0.35%
Ins Owner Change3.34%
Market Cap1.79B
Analysts84.71
Price Target101.18 (96.05%)
Short Float %11.36%
Short Ratio6.95
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)12.24%
Min EPS beat(2)11.71%
Max EPS beat(2)12.77%
EPS beat(4)4
Avg EPS beat(4)12.69%
Min EPS beat(4)9.14%
Max EPS beat(4)17.14%
EPS beat(8)6
Avg EPS beat(8)9.41%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.81%
PT rev (3m)4.82%
EPS NQ rev (1m)-0.92%
EPS NQ rev (3m)4.19%
EPS NY rev (1m)2.73%
EPS NY rev (3m)6.67%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.71
P/tB 2.71
EV/EBITDA N/A
EPS(TTM)-3.92
EYN/A
EPS(NY)-5.15
Fwd EYN/A
FCF(TTM)-2.97
FCFYN/A
OCF(TTM)-2.94
OCFYN/A
SpS0
BVpS19.07
TBVpS19.07
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -16.42%
ROE -17.64%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-22.05%
ROA(5y)-23.6%
ROE(3y)-24.43%
ROE(5y)-26.32%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 859.33%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 37.65
Quick Ratio 37.65
Altman-Z 21.79
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)193.13%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-18.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%6.42%
EPS Next Y-19.64%
EPS Next 2Y-13.62%
EPS Next 3Y-0.99%
EPS Next 5Y19.23%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-41.8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-41.42%
EBIT Next 3Y16.66%
EBIT Next 5YN/A
FCF growth 1Y-60.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-58.86%
OCF growth 3YN/A
OCF growth 5YN/A